Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. India
  4. NSE India Stock Exchange
  5. Divi's Laboratories Limited
  6. News
  7. Summary
    DIVISLAB   INE361B01024

DIVI'S LABORATORIES LIMITED

(DIVISLAB)
  Report
Delayed Quote. Delayed NSE India Stock Exchange - 12/03 06:25:27 am
4757.05 INR   -0.42%
12/01Indian Indices Settle in Green Midweek; IndusInd Bank Soars 6%
MT
11/26Indian Indices End Lower on Friday; JSW Steel Plunges 8%
MT
11/25Indian Indices Close Higher on Thursday; Reliance Industries Jumps 6%
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Indian shares snap four-day losing streak as banks, pharma stocks take lead

10/04/2021 | 06:32am EST

BENGALURU, Oct 4 (Reuters) - Indian shares closed higher on Monday after falling for four straight sessions, boosted by banking and pharmaceutical stocks, with investors now eyeing a central bank policy meeting and the start of the domestic corporate results season.

The blue-chip NSE Nifty 50 index ended 0.91% higher at 17,691.25, while the benchmark S&P BSE Sensex rose 0.91% to 59,299.32.

The indexes last week had posted their worst weekly performance in several months, as the market consolidated after touching several record highs in September when lower COVID-19 cases prompted an easing in restrictions across the country.

Looking ahead, a meeting by the Reserve Bank of India is on investors' radar as it could point towards an unwinding of its accommodative monetary policy, while IT firm Tata Consultancy Services will kickstart September-quarter earnings season when it announces its results on Friday.

Among individual shares and sectors, public sector banks jumped more than 2% on Monday to drive gains on the benchmark index, with Union Bank of India rising over 3%.

Pharmaceutical stocks advanced 1.5%. Divi's Laboratories surged 8% after global drugmaker Merck & Co reported positive trial results for its COVID-19 pill, the main ingredient of which is made by Divi's Labs.

Energy shares added 1.5%, while tech stocks also climbed.

Gains in the energy sector was driven by power retailer NTPC Ltd as it rose more than 4%, after media reports of the company looking to raise 150 bln rupees ($2.02 bln) through IPOs in three units.

(Reporting by Soumyajit Saha in Bengaluru; editing by Uttaresh.V)


ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
DIVI'S LABORATORIES LIMITED -0.42% 4757.05 Delayed Quote.23.82%
NTPC LTD -1.32% 127 Delayed Quote.27.83%
TATA CONSULTANCY SERVICES LTD. -0.07% 3640.45 Delayed Quote.27.17%
UNION BANK OF INDIA -0.54% 46 End-of-day quote.45.80%
All news about DIVI'S LABORATORIES LIMITED
12/01Indian Indices Settle in Green Midweek; IndusInd Bank Soars 6%
MT
11/26Indian Indices End Lower on Friday; JSW Steel Plunges 8%
MT
11/25Indian Indices Close Higher on Thursday; Reliance Industries Jumps 6%
MT
11/08Indian Indices Close Higher on Monday; IndusInd Bank Plummets 10%
MT
11/08Indian shares rise on financial, energy boost; Pfizer local unit jumps
RE
11/08Indian shares rise on financial, energy boost; Pfizer local unit jumps
RE
11/08Private banks, pharma weigh on India shares; Pfizer India unit jumps
RE
11/07Divi's Laboratories Logs Higher Fiscal Q2 Consolidated Net Profit
MT
11/06Divi's Laboratories Limited Reports Earnings Results for the Second Quarter and Six Mon..
CI
10/27Indian Indices Close Lower Midweek; Axis Bank Slumps 6%
MT
More news
Financials
Sales 2022 82 660 M 1 099 M 1 099 M
Net income 2022 24 640 M 327 M 327 M
Net cash 2022 25 926 M 345 M 345 M
P/E ratio 2022 51,4x
Yield 2022 0,51%
Capitalization 1 263 B 16 782 M 16 785 M
EV / Sales 2022 15,0x
EV / Sales 2023 12,5x
Nbr of Employees 16 818
Free-Float 47,7%
Chart DIVI'S LABORATORIES LIMITED
Duration : Period :
Divi's Laboratories Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DIVI'S LABORATORIES LIMITED
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 15
Last Close Price 4 757,05 INR
Average target price 5 228,63 INR
Spread / Average Target 9,91%
EPS Revisions
Managers and Directors
Satchandra Kiran Divi Chief Executive Officer & Executive Director
L. Kishore Babu Chief Financial Officer
Ramesh B. V. Nimmagadda Non-Executive Chairman
L. Ramesh Babu Chief Information Officer & VP-Procurement
Ramesh Babu M. General Manager-Technical Operations
Sector and Competitors
1st jan.Capi. (M$)
DIVI'S LABORATORIES LIMITED23.82%16 782
JOHNSON & JOHNSON1.27%419 583
ROCHE HOLDING AG17.62%341 364
PFIZER, INC.44.09%304 610
NOVO NORDISK A/S64.51%244 010
ELI LILLY AND COMPANY47.55%222 641